6-(2-hydroxybenzylamino)-9-β-D-2'-deoxyribofuranosylpurine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-(2-hydroxybenzylamino)-9-β-D-2'-deoxyribofuranosylpurine
• 英文别名: N⁶-(o-hydroxybenzyl)-2'-deoxyadenosine；N6-(o-hydroxybenzyl)-2'-deoxyadenosine；(2R,3S,5R)-2-(hydroxymethyl)-5-[6-[(2-hydroxyphenyl)methylamino]purin-9-yl]oxolan-3-ol
• 化学式: C₁₇H₁₉N₅O₄
• 分子量: 357.369
• InChiKey: CCYLRAYLVGARQT-BFHYXJOUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  9-(3,5-di-O-acetyl-2-deoxy-β-D-erythro-pentofuranosyl)-6-bromopurine 在 氨 、 三乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 11.0h， 生成 6-(2-hydroxybenzylamino)-9-β-D-2'-deoxyribofuranosylpurine
  参考文献：
  名称：

  Ｎ６−置換アデノシン誘導体とＮ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途

  摘要：

  该专利涉及调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品的组合。解决方案特点在于选择自特定化合物组中的N6-取代腺苷诱导体或N6-取代腺嘌呤诱导体。此外，医药组合物特点在于至少包含治疗有效量的上述化合物和药学上可接受的载体。进一步，该化合物特点在于用于调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品。【选择图】无

  公开号：

  JP2015172077A

文献信息

• [EN] 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF<br/>[FR] 6-ARYL-9-GLYCOSYLPURINES ET LEUR UTILISATION
  申请人：UNIV PALACKEHO

  公开号：WO2016091236A1

  公开（公告）日：2016-06-16

  The present invention provides 6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein Gly represents β-D-arabinofuranosyl or β-D-2´-deoxyribofuranosyl, Ar represents benzyl or furfuryl, each of which can be unsubstituted or substituted by one or more, preferably one to three, substituents selected from the group comprising hydroxyl, alkyl, halogen, alkoxy, amino, mercapto, carboxyl, cyano, amido, sulfo, sulfamido, acyl, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, trifluoromethyl, trifluoromethoxy, for use for regulation, in particular inhibition, of aging in plants in vivo or plant cells in vitro, and for regulation of growth and development of plants in vivo, plant tissues, plant organs and plant cells in vitro..

  本发明提供了通式I的6-芳基-9-糖苷嘌呤及其与碱金属、氨、胺或酸的加合盐，其中Gly代表β-D-阿拉伯呋喃糖苷或β-D-2´-脱氧核糖呋喃糖苷，Ar代表苄基或呋喃甲基，每个都可以是未取代的或被一个或多个，优选一个至三个，羟基、烷基、卤素、烷氧基、氨基、巯基、羧基、氰基、酰胺基、磺酰基、磺胺基、酰基、酰胺基、酰氧基、烷基氨基、二烷基氨基、烷基巯基、三氟甲基、三氟甲氧基等取代基所取代，用于调节植物体内或植物细胞体外的衰老，特别是抑制衰老，并用于调节植物体内、植物组织、植物器官和植物细胞体外的生长和发育。
• N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF
  申请人：Shi Jiangong

  公开号：US20130045942A1

  公开（公告）日：2013-02-21

  The present invention provides N 6 -substituted adenosine derivatives and N 6 -substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

  本发明提供了N6-取代腺苷衍生物和N6-取代腺嘌呤衍生物，其制备方法，包括上述化合物的药物组合物，以及这些化合物在制造治疗失眠、惊厥、癫痫和帕金森病的药物和保健产品以及预防和治疗痴呆症中的用途。
• EP2511283
  申请人：——

  公开号：——

  公开（公告）日：——
• Alkylation of Nucleic Acids by a Model Quinone Methide
  作者：Praveen Pande、Jason Shearer、Jianhong Yang、William A. Greenberg、Steven E. Rokita

  DOI：10.1021/ja990456k

  日期：1999.7.1

  Quinone methides and related electrophiles represent a common class of intermediates that form during metabolism of drugs and xenobiotics and may lead to DNA alkylation. The intrinsic reactivity of these species has now been characterized using a stable model compound, O-(tert-butyldimethylsilyl)-2-bromomethylphenol, designed to generate an o-quinone methide in the presence of fluoride. The resulting deoxynucleoside adducts were assigned unambiguously through use of two-dimensional NMR and,in particular, heteronuclear multiple-bond connectivity (HMBC); Both purines, dG and dA, reacted at their exo-amino groups. In contrast, dC had previously been shown to react at its cyclic N3 position [Rokita, S. E.; Yang, J.; Pande, P.; Greenberg, W. A. J. Org. Chem. 1997, 62, 3010-3012], and the relatively nonnucleophilic T remained inert under all conditions examined. Surprisingly, the efficiency of cytosine modification exceeded that of adenine and guanine by more than 10-fold in competition studies with the deoxymononucleosides. Reaction of all residues was suppressed in duplex DNA, but none was affected more than cytosine (>3600-fold). Guanine consequently emerged as the predominant target in duplex DNA in accord with the selectivity of most natural products forming quinone methide-like species. These general observations may then in part reflect the ability of the exo-amino group of guanine to maintain its reactivity most effectively from nucleoside to helical DNA.
• Ｎ６−置換アデノシン誘導体とＮ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
  申请人：中国医学科学院葯物研究所

  公开号：JP2015172077A

  公开（公告）日：2015-10-01

  【課題】鎮痛剤、催眠、抗痙攣薬、抗てんかん薬、抗パーキンソン病や認知症予防薬や健康食品の調整を行うこと。【解決手段】特定の化合物のグループから選択されることを特徴とする、Ｎ６−置換アデノシン誘導体またはＮ６−置換アデニン誘導体。 また、治療上有効な量の上記化合物と、薬学的に許容される担体とを少なくとも含有することを特徴とする、医薬組成物。 さらに、鎮痛剤、催眠、抗痙攣薬、抗てんかん薬、抗パーキンソン病や認知症予防薬や健康食品の調整において使用されることを特徴とする、上記化合物。【選択図】なし

  该专利涉及调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品的组合。解决方案特点在于选择自特定化合物组中的N6-取代腺苷诱导体或N6-取代腺嘌呤诱导体。此外，医药组合物特点在于至少包含治疗有效量的上述化合物和药学上可接受的载体。进一步，该化合物特点在于用于调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品。【选择图】无